August 2009 Volume 9 Number 8
Visit Nature Reviews Cancer online to browse the journal.
Now available at http://links.ealert.nature.com/ctt?kn=17&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access
to Nature Reviews Cancer online. To purchase a subscription,
please visit: http://links.ealert.nature.com/ctt?kn=21&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=38&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
*********************************************************************
Nature Reviews Cancer Impact Factor: 30.762*
* 2008 Journal Citation Report (Thomson Reuters, 2009)
*********************************************************************
=========================== ADVERTISEMENT ===========================
The NEW xCELLigence RTCA DP Instrument from Roche Applied Science obtains
data from three independent 16 well E-Plates simultaneously. Discover the
various applications of continuous, label-free real-time cellular analysis
by impedance measurement. For more information click below:
http://links.ealert.nature.com/ctt?kn=18&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
IT'S NOW FREE TO POST YOUR VACANCY ON
naturejobs.com
http://links.ealert.nature.com/ctt?kn=93&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
It's the breakthrough you've been waiting for. Naturejobs.com - the
scientific jobs board from Nature now lets you advertise your vacancy
completely FREE OF CHARGE
Go to http://links.ealert.nature.com/ctt?kn=16&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0 or telephone:
Europe: +44 (0) 20 78434961
US: + 1 800 9897718
=========================== ADVERTISEMENT ===========================
Nature Reviews Cancer
2008 Impact Factor: 30.762*
For its 5th consecutive year, Nature Reviews Cancer is the number one cited
monthly review journal in oncology. Ensure you have access to the 'must-read'
review journal of cancer researchers worldwide.
Subscribe today at a 20% discount:
http://links.ealert.nature.com/ctt?kn=85&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
Recommend to your library:
http://links.ealert.nature.com/ctt?kn=32&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
* 2008 Journal Citation Reports (Thomson Reuters, 2009)
=========================== ADVERTISEMENT ===========================
This month's Featured article:
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
p550 | doi:10.1038/nrc2664
http://links.ealert.nature.com/ctt?kn=94&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
=====================================================================
From the editors
p527 | doi:10.1038/nrc2712
http://links.ealert.nature.com/ctt?kn=40&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
----------------------
RESEARCH HIGHLIGHTS
----------------------
Chromosomal instability: It's about the geometry
p529 | doi:10.1038/nrc2697
http://links.ealert.nature.com/ctt?kn=47&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
Metastasis: WAVEing goodbye to invasion
p530 | doi:10.1038/nrc2699
http://links.ealert.nature.com/ctt?kn=50&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
Endocytosis: Increased trafficking
p530 | doi:10.1038/nrc2704
http://links.ealert.nature.com/ctt?kn=26&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
IN THE NEWS
Making waves
p530 | doi:10.1038/nrc2711
http://links.ealert.nature.com/ctt?kn=7&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
Metastasis: T-ALL order
p531 | doi:10.1038/nrc2701
http://links.ealert.nature.com/ctt?kn=95&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
IN BRIEF
Signalling | Metastasis | Metabolism | Signalling
p532 | doi:10.1038/nrc2707
http://links.ealert.nature.com/ctt?kn=4&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
Therapy: microRNA suppresses liver cancer
p532 | doi:10.1038/nrc2708
http://links.ealert.nature.com/ctt?kn=105&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
Non-coding RNA: Dicing with lung cancer
p532 | doi:10.1038/nrc2709
http://links.ealert.nature.com/ctt?kn=102&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
TRIAL WATCH
Synthetic lethal success | Anti-VEGF alternative
p533 | doi:10.1038/nrc2706
http://links.ealert.nature.com/ctt?kn=11&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
Therapy: Special delivery
p534 | doi:10.1038/nrc2702
http://links.ealert.nature.com/ctt?kn=56&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
Tumorigenesis: Cone cells set the stage
p534 | doi:10.1038/nrc2710
http://links.ealert.nature.com/ctt?kn=46&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
Cancer pain: Getting on my nerves
p535 | doi:10.1038/nrc2705
http://links.ealert.nature.com/ctt?kn=82&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
----------------------
REVIEWS
----------------------
Signal integration by JNK and p38 MAPK pathways in cancer development
Erwin F. Wagner and Angel R. Nebreda
p537 | doi:10.1038/nrc2694
Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase
(MAPK) signalling pathways are involved in a vast array of cellular
events and are often altered in human cancers. This Review discusses
how studies in mouse models have contributed to our understanding of
the functions of these pathways in different cancers, and the implications
for therapeutic approaches.
Abstract: http://links.ealert.nature.com/ctt?kn=42&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=97&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
p550 | doi:10.1038/nrc2664
The PI3K-Akt pathway is vital to the growth and survival of cancer cells
and consequently inhibitors targeting this pathway are entering clinical
trials. What is the therapeutic potential of such drugs and what might
the challenges and limitations be?
Abstract: http://links.ealert.nature.com/ctt?kn=94&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=62&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression
David B. Shackelford and Reuben J. Shaw
p563 | doi:10.1038/nrc2676
The human tumour suppressor LKB1 directly phosphorylates and activates
AMPK, a central metabolic sensor. AMPK is a key therapeutic target in
patients with diabetes, and the connection between AMPK and several
tumour suppressors suggests that therapeutic manipulation of this pathway
using established diabetes drugs warrants investigation in patients with cancer.
Abstract: http://links.ealert.nature.com/ctt?kn=30&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=28&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
Article series: Therapeutic resistance
http://links.ealert.nature.com/ctt?kn=10&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
CYP2D6 and tamoxifen: DNA matters in breast cancer
Janelle M. Hoskins, Lisa A. Carey and Howard L. McLeod
p576 | doi:10.1038/nrc2683
The pharmacological activity of tamoxifen is dependent on metabolic
conversion by the enzyme cytochrome P450 2D6 (CYP2D6). This Review
discusses the existing data that relate CYP2D6 genotypes to tamoxifen
response. Can the analysis of CYP2D6 genotype be used to optimize breast
cancer therapy?
Abstract: http://links.ealert.nature.com/ctt?kn=20&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=101&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
----------------------
PERSPECTIVES
----------------------
OPINION
Crosstalk of Notch with p53 and p63 in cancer growth control
G. Paolo Dotto
p587 | doi:10.1038/nrc2675
This Opinion article focuses on the multilevel crosstalk between the
Notch pathway and the p53 and p63 pathways. Can selective or combined
targeting of these pathways improve the efficacy and reduce the toxicity
of cancer therapies?
Abstract: http://links.ealert.nature.com/ctt?kn=23&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=60&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
SCIENCE AND SOCIETY
Assessing cancer risks of low-dose radiation
Leon Mullenders, Mike Atkinson, Herwig Paretzke, Laure Sabatier and Simon Bouffler
p596 | doi:10.1038/nrc2677
A major challenge exists in assessing the risk of developing cancer from
exposures to low-dose radiation - which are encountered during
diagnostic scans, for example. What factors influence low-dose cancer
risk and what might this mean for current protection measures?
Abstract: http://links.ealert.nature.com/ctt?kn=90&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=36&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
Corrigendum: High throughput insertional mutagenesis screens in mice
to identify oncogenic networks
Jaap Kool and Anton Berns
p604 | doi:10.1038/nrc2700
http://links.ealert.nature.com/ctt?kn=12&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
Corrigendum: Science and society : Wildlife cancer: a conservation perspective
Denise McAloose and Alisa L. Newton
p605 | doi:10.1038/nrc2698
http://links.ealert.nature.com/ctt?kn=59&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
FREE ARTICLE
Huntington's Disease: A major advance
Johns Hopkins researchers may have solved a central mystery of Huntington's
disease: why the mutant form of the huntingtin protein occurs throughout the
body and yet causes pathology primarily in the brain. The proposed target,
Rhes, also looks to be druggable. Find out more by reading the first in-depth
analysis of the scientific and commercial potential of the work in
SciBX: Science-Business eXchange.
Full text: http://links.ealert.nature.com/ctt?kn=78&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
PDF: http://links.ealert.nature.com/ctt?kn=72&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
**************************************************************************************
ACCESS 20 FREE ARTICLES from the SciBX Cover Story Archive HERE
http://links.ealert.nature.com/ctt?kn=70&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted in to
receive it. You can change or discontinue your e-mail alerts at any time,
by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=13&m=33705079&r=MTc2Njc4NzkyNgS2&b=2&j=NTM3OTI5MTMS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
